

# SCOLR Pharma Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

<https://marketpublishers.com/r/SBA3B53704DBEN.html>

Date: May 2025

Pages: 50

Price: US\$ 499.00 (Single User License)

ID: SBA3B53704DBEN

## Abstracts

SCOLR Pharma Inc. Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between SCOLR Pharma Inc. and its competitors. This provides our Clients with a clear understanding of SCOLR Pharma Inc. position in the [Pharmaceuticals and Biotechnology](#) Industry.

The report contains detailed information about SCOLR Pharma Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.

Another part of the report is a SWOT-analysis carried out for SCOLR Pharma Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.

The SCOLR Pharma Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-

term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.

In the part that describes SCOLR Pharma Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.

Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of SCOLR Pharma Inc. business.

### **About SCOLR Pharma Inc.**

SCOLR Pharma, Inc., a specialty pharmaceutical company, develops and commercializes prescription, over-the-counter (OTC), and nutritional products. The company uses its proprietary and patented controlled delivery technology (CDT) platform to develop its products.

#### **Product Development**

The company's proprietary drug delivery technologies are applicable to a range of drugs with different physical and chemical properties, including water soluble and insoluble drugs, as well as high dose and low dose drugs. Using its CDT platforms, the company can formulate drugs with precise release profiles.

The company's CDT technologies have been used to develop various dietary supplement products that are manufactured and distributed by third parties. It receives royalties and other payments from the sale of products that incorporate its CDT technology, including combinations of glucosamine and chondroitin, calcium, and other dietary products. It has introduced approximately 10 different extended release dietary supplements to the U.S. retailers and pharmacy outlets.

The company also has applied its CDT platforms to a portfolio of approximately 20 pharmaceutical targets on a developmental basis. These target candidates include existing analgesic, cardiovascular, diabetes, anti-nausea, and pulmonary products. It is advancing ibuprofen and pseudoephedrine towards commercialization.

### Development Status of Lead Products

**Ibuprofen**—The company's primary drug product candidate is a 12 hour extended release formulation of ibuprofen, an analgesic typically used for the treatment of pain, fever, and inflammation. The company completed its pivotal Phase III trial demonstrating safety and efficacy of its 12 hour 600 mg extended release ibuprofen for the OTC market.

**Pseudoephedrine**— The company's 12 hour pseudoephedrine product is a decongestant that is used to relieve sinus pressure related to allergies and the common cold.

### Nutritional Products

The company has developed multiple private label extended release nutritional products incorporating its CDT technology for commercialization in the United States and Canada.

### Commercial Relationships

In 2009, the company entered into a license agreement with Chrono Nutraceuticals LLC, a newly formed Arizona limited liability company (Chrono), providing Chrono with rights in Canada to manufacture and sell four extended release dietary supplements using its proprietary CDT drug delivery platform. In addition, the company granted Chrono the rights to manufacture and sell two of such products in the United States.

The company has a manufacture, license, and distribution agreement with Perrigo Company of South Carolina, Inc. (Perrigo). Under the agreement, the company has granted Perrigo a license to its CDT technology for the manufacture, marketing, distribution, sale, and use of specific dietary supplement products in the United States.

The company has entered into research collaboration with BioCryst Pharmaceuticals INC. (BioCryst) to develop an oral formulation of peramivir, using its CDT platforms. Peramivir is a novel therapeutic being developed by BioCryst for treatment of seasonal

and life threatening influenza with a focus on intravenous and intramuscular delivery.

## Competition

The company's major competitors in the drug delivery field include Biovail, Inc.; Penwest; SkyePharma PLC; Depomed; Elan Corporation, PLC; Flamel Technologies, Inc.; Impax Laboratories, Inc.; Labopharm, Inc.; and KV Pharmaceutical Company.

## History

The company was founded in 1983. It was formerly known as Caddy Systems, Inc. and changed its name to Nutraceutix, Inc. in 1995. Further, it changed its name to SCOLR, Inc. in 2002; and to SCOLR Pharma, Inc. in 2004.

The above Company Fundamental Report is a half-ready report and contents are subject to change.

It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

## Contents

RESEARCH METHODOLOGY

DISCLAIMER

### **1. SCOLR PHARMA INC. COMPANY PROFILE**

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

### **2. SCOLR PHARMA INC. BUSINESS OVERVIEW**

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

### **3. SCOLR PHARMA INC. SWOT ANALYSIS**

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

### **4. SCOLR PHARMA INC. FINANCIAL ANALYSIS**

- 4.1. Financial Statements
  - 4.1.1. Income Statement
  - 4.1.2. Balance Sheet
  - 4.1.3. Cash Flow
- 4.2. Financial Ratios
  - 4.2.1. Profitability
  - 4.2.2. Margin Analysis

- 4.2.3. Asset Turnover
- 4.2.4. Credit Ratios
- 4.2.5. Long-Term Solvency
- 4.2.6. Growth Over Prior Year
- 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

## **5. SCOLR PHARMA INC. COMPETITORS AND INDUSTRY ANALYSIS**

- 5.1. SCOLR Pharma Inc. Direct Competitors
- 5.2. Comparison of SCOLR Pharma Inc. and Direct Competitors Financial Ratios
- 5.3. Comparison of SCOLR Pharma Inc. and Direct Competitors Stock Charts
- 5.4. SCOLR Pharma Inc. Industry Analysis
  - 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  - 5.4.2. SCOLR Pharma Inc. Industry Position Analysis

## **6. SCOLR PHARMA INC. NEWS & EVENTS**

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

## **7. SCOLR PHARMA INC. EXPERTS REVIEW<sup>1</sup>**

- 7.1. Experts Consensus
- 7.2. Experts Revisions

## **8. SCOLR PHARMA INC. ENHANCED SWOT ANALYSIS<sup>2</sup>**

## **9. UNITED STATES PESTEL ANALYSIS<sup>2</sup>**

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors

## **10. SCOLR PHARMA INC. IFE, EFE, IE MATRICES<sup>2</sup>**

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix

## **11. SCOLR PHARMA INC. PORTER FIVE FORCES ANALYSIS<sup>2</sup>**

## **12. SCOLR PHARMA INC. VRIO ANALYSIS<sup>2</sup>**

### **APPENDIX: RATIO DEFINITIONS**

### **LIST OF FIGURES**

SCOLR Pharma Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit  
Profit Margin Chart  
Operating Margin Chart  
Return on Equity (ROE) Chart  
Return on Assets (ROA) Chart  
Debt to Equity Chart  
Current Ratio Chart  
SCOLR Pharma Inc. 1-year Stock Charts  
SCOLR Pharma Inc. 5-year Stock Charts  
SCOLR Pharma Inc. vs. Main Indexes 1-year Stock Chart  
SCOLR Pharma Inc. vs. Direct Competitors 1-year Stock Charts  
SCOLR Pharma Inc. Article Density Chart

1 – Data availability depends on company's security policy.

2 – These sections are available only when you purchase a report with appropriate additional types of analyses.  
The complete financial data is available for publicly traded companies.

## List Of Tables

### LIST OF TABLES

SCOLR Pharma Inc. Key Facts  
Profitability  
Management Effectiveness  
Income Statement Key Figures  
Balance Sheet Key Figures  
Cash Flow Statement Key Figures  
Financial Performance Abbreviation Guide  
SCOLR Pharma Inc. Key Executives  
SCOLR Pharma Inc. Major Shareholders  
SCOLR Pharma Inc. History  
SCOLR Pharma Inc. Products  
Revenues by Segment  
Revenues by Region  
SCOLR Pharma Inc. Offices and Representations  
SCOLR Pharma Inc. SWOT Analysis  
Yearly Income Statement Including Trends  
Income Statement Latest 4 Quarters Including Trends  
Yearly Balance Sheet Including Trends  
Balance Sheet Latest 4 Quarters Including Trends  
Yearly Cash Flow Including Trends  
Cash Flow Latest 4 Quarters Including Trends  
SCOLR Pharma Inc. Profitability Ratios  
Margin Analysis Ratios  
Asset Turnover Ratios  
Credit Ratios  
Long-Term Solvency Ratios  
Financial Ratios Growth Over Prior Year  
SCOLR Pharma Inc. Capital Market Snapshot  
SCOLR Pharma Inc. Direct Competitors Key Facts  
Direct Competitors Profitability Ratios  
Direct Competitors Margin Analysis Ratios  
Direct Competitors Asset Turnover Ratios  
Direct Competitors Credit Ratios  
Direct Competitors Long-Term Solvency Ratios  
Pharmaceuticals and Biotechnology Industry Statistics



SCOLR Pharma Inc. Industry Position  
Company vs. Industry Income Statement Analysis  
Company vs. Industry Balance Sheet Analysis  
Company vs. Industry Cash Flow Analysis  
Company vs. Industry Ratios Comparison  
SCOLR Pharma Inc. Consensus Recommendations<sup>1</sup>  
Analyst Recommendation Summary<sup>1</sup>  
Price Target Summary<sup>1</sup>  
Experts Recommendation Trends<sup>1</sup>  
Revenue Estimates Analysis<sup>1</sup>  
Earnings Estimates Analysis<sup>1</sup>  
Historical Surprises<sup>1</sup>  
Revenue Estimates Trend<sup>1</sup>  
Earnings Estimates Trend<sup>1</sup>  
Revenue Revisions<sup>1</sup>

## ANALYSIS FEATURES

### SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

### Enhanced SWOT Analysis

Enhanced SWOT is a 3x3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

How to use the strengths to take advantage of the opportunities?

How to use the strengths to reduce likelihood and impact of the threats?

How to overcome the weaknesses that obstruct taking advantage of the opportunities?

How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

### PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

## Key Factors Examined by PESTEL Analysis:

**Political** – What opportunities and pressures are brought by political bodies and what is the degree of public regulations' impact on the business?

**Economic** – What economic policies, trends and structures are expected to affect the organization, what is this influence's degree?

**Sociological** – What cultural and societal aspects will work upon the demand for the business's products and operations?

**Technological** – What impact do the technological aspects, innovations, incentives and barriers have on the organization?

**Environmental** – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?

**Legal** – What laws and legislation will exert influence on the style the business is carried out?

## **IFE, EFE, IE Matrices**

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business's functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors

integrated into one suggestive model.

## **Porter Five Forces Analysis**

The Porter's five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

What composes a threat of substitute products and services?

Is there a threat of new competitors entering the market?

What is the intensity of competitive rivalry?

How big is the bargaining power of buyers?

How significant is the bargaining power of suppliers?

## **VRIO Analysis**

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company's resources and capabilities and bring them together into one aggregate table that includes:

Tangible resources

Financial

Physical

Technological

Organizational

Intangible resources

Human

Innovation and Creativity

## Reputation

### Organizational capabilities

The result of the analysis gives a clear picture of company's competitive and economic implications, answering the questions if the resources mentioned above are:

Valuable?

Rare?

Costly to imitate?

Organized properly?

## I would like to order

Product name: SCOLR Pharma Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Product link: <https://marketpublishers.com/r/SBA3B53704DBEN.html>

Price: US\$ 499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SBA3B53704DBEN.html>